---
title: "NEPG: The holding subsidiary has obtained approval for drug clinical trials"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/260252068.md"
description: "NEPG announced that its holding subsidiary Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. has received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration. The drug name is DCTY0801 injection, and the indication is for EGFRvIII positive recurrent or progressive high-grade glioma. The approval of this clinical trial is an important milestone in the research and development process of this product, which will accelerate the progress of the company's research products and enhance the company's core competitiveness in the field of cancer treatment"
datetime: "2025-10-08T08:34:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/260252068.md)
  - [en](https://longbridge.com/en/news/260252068.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/260252068.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/260252068.md) | [English](https://longbridge.com/en/news/260252068.md)


# NEPG: The holding subsidiary has obtained approval for drug clinical trials

NEPG announced that its holding subsidiary Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The drug name is DCTY0801 injection, and the indication is for EGFRvIII positive recurrent or progressive high-grade glioma. The approval of this clinical trial is an important milestone in the research and development process of this product, which will accelerate the progress of the company's research products and enhance the company's core competitiveness in the field of cancer treatment

### 相關股票

- [NEPG (000597.CN)](https://longbridge.com/zh-HK/quote/000597.CN.md)

## 相關資訊與研究

- [Hengrui Pharmaceuticals Gets Nod to Trial SHR-9803 for Injection](https://longbridge.com/zh-HK/news/278830096.md)
- [Xenon Pharmaceuticals Shares Surge on Positive Study Data for Azetukalner](https://longbridge.com/zh-HK/news/278422121.md)
- [GLP-1 Feud Ends: NOVO, HIMS Join Forces (Again) To Sell Obesity Drugs](https://longbridge.com/zh-HK/news/278234512.md)
- [09:45 ETMedical Knowledge Group Appoints David Margines to Board of Directors, Advancing Its Legacy in AI- and Analytics-Driven Drug Commercialization](https://longbridge.com/zh-HK/news/278896967.md)
- [Ionis Pharmaceuticals (IONS) Valuation Check As FDA Grants Priority Review For Olezarsen](https://longbridge.com/zh-HK/news/278239371.md)